CN109942574B - Tianqitinib and preparation method and application thereof - Google Patents
Tianqitinib and preparation method and application thereof Download PDFInfo
- Publication number
- CN109942574B CN109942574B CN201910028222.7A CN201910028222A CN109942574B CN 109942574 B CN109942574 B CN 109942574B CN 201910028222 A CN201910028222 A CN 201910028222A CN 109942574 B CN109942574 B CN 109942574B
- Authority
- CN
- China
- Prior art keywords
- compound
- mass
- organic solvent
- reaction
- volume ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention provides an amide-substituted azaindole compound or a pharmaceutically acceptable salt thereof, or a solvate thereof or a prodrug thereof, and provides a structure shown in formula I. The compound prepared by the invention can obviously inhibit the enzyme activity of TRK at a molecular level, has an obvious inhibiting effect on the phosphorylation/activation of TRK at a cell level, can obviously inhibit the growth of human tumor cell strain nude mouse transplantation tumor, and has a wide market application prospect.
Description
Technical Field
The invention relates to the field of drug synthesis, in particular to a preparation method and application of an amide-substituted azaindole compound (nitazotinib).
Background
The treatment of malignant tumors has long been a worldwide problem that is a serious life-threatening problem for humans, and despite advances in the level of diagnosis and treatment, the survival rates of many tumor patients have been low. Several new anti-tumor targets have been discovered in recent years, of which tyrosine kinase has become a new promising anti-tumor target.
TRK is a high affinity receptor tyrosine kinase activated by a group of soluble growth factors called neurotrophic factors (NTs). The TRK receptor family has 3 members, i.e., TRKA, TRKB, and TRKC. Among the neurotrophic factors are Neurotrophic Growth Factor (NGF), which activates TRKA, brain-derived neurotrophic factor (BDNF) and NT-4/5, which activates TRKB, and NT3, which activates TRKC. TRK is widely expressed in neuronal tissue and is involved in the maintenance, signaling and survival of neuronal cells (Patapoutian, A. et al, Current Opinion in Neurobiology,2001,11, 272-.
Recent literature has shown that overexpression, activation, amplification and/or mutation of TRK is associated with many tumors. The tumors include neuroblastoma (Brodeur, G.M., Nat.Rev. Cancer2003,3, 203-2161), ovarian Cancer (Davidson.B. et al, Clin.cancer Res.2003,9,2248-2259), breast Cancer (Kruettgen et al, Brain Pathology2006,16:304 310), prostate Cancer (Dionne et al, Clin.cancer Res.1998,4(8):1887-1898), pancreatic Cancer (Dang et al, Journal of Gastroenterology and Hepatology2006,21(5):850-858), multiple myeloma (Hutch et al, Cancer Genetics and cytogenomics 2032007, 178:1-10), astrocytoma and medulloblastoma (Kruettron et al, Brauin et al, Brabender et al, Cancer Res.2007, 16: 2007, thyroid Cancer (Corynebacterium parvugula et al, 22, 300-275), melanoma (Leuconquer et al, 300-310, leukemia, 14-103, leukemia, 14, 103, leukemia, melanoma (Bruettron et al, 300, 103, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, melanoma, leukemia, molecular and Cellular biochemistry2007,295(1&2), 19-26), large cell neuroendocrine tumors (Marc hetero ti et al, Human Mutation2008, 29(5), 609-.
In preclinical models of cancer, TRK inhibitors are effective in inhibiting tumor growth and preventing tumor metastasis. In particular, non-selective small molecule inhibitors of TRKA, B and C and TRK/Fc chimeras are effective in inhibiting tumor growth and preventing tumor metastasis (Nakagawara, A (2001) Cancer Letters 169: 107-. Therefore, inhibitors of the TRK family of kinases have utility in the treatment of cancer.
International patent application publications WO2009/081197, WO2016/096709 and WO2006/087538 describe several types of small molecules that are TRK kinase inhibitors that may be used to treat cancer. Among them, LOXO-101 has been approved by the FDA at 26.11 months at 2108 for the treatment of solid tumors carrying NTRK gene fusions, non-surgical resection or metastases.
The TRK kinase inhibitor is clinically used for tumor research, and has obvious data effect. Therefore, more safe and effective TRK kinase inhibitors are needed. The inventor designs and synthesizes amide substituted azaindole compounds with novel structures, and discovers a small molecule drug with good activity at enzyme level, cell level and in vivo experiments by optimizing substituent groups.
Disclosure of Invention
In view of the deficiencies of the prior art, the present invention provides a compound having the structure shown in formula I, named: n- (5- (3, 5-difluoroanilino) -1H-pyrazolo [2,3-b ] pyridin-3-yl) -4- (4-methylpiperazin-1-yl) -2- (tetrahydro-2H-pyran-4-yl) benzamide and was designated: tianqitinib.
The invention provides an amide substituted azaindole compound or pharmaceutically acceptable salt thereof, or solvate thereof or prodrug thereof, wherein the compound has a structure shown in formula I:
the invention also provides a preparation method of the compound shown in the formula I, which is characterized by comprising the following steps: the method comprises the following steps:
(1) adding 5-bromo-7-azaindole into a solution of nitrate and concentrated sulfuric acid to perform nitration reaction, and after the reaction is finished, dropping the system into ice water to separate out a solid to obtain a compound 2;
(2) adding a reducing agent and ammonium chloride into the compound 2 obtained in the step (1), adding an organic solvent, carrying out reduction reaction, filtering after the reaction is finished, taking liquid, concentrating and removing the solvent to obtain a compound 3;
(3) i, dissolving the 4 of the compound in an organic solvent a, dropwise adding oxalyl chloride, stirring, and concentrating the liquid for later use; adding triethylamine and an organic solvent b into the compound 3 obtained in the step (2); iii, dissolving the standby system obtained in the step i in an organic solvent c under stirring, and then, dripping the organic solvent into the system obtained in the step ii to perform condensation reaction; after the reaction is finished, the compound 5 is obtained by purification.
(4) Adding 3, 5-difluoroaniline, 1 '-binaphthyl-2, 2' -bis-diphenylphosphine, cesium carbonate, palladium acetate and dioxane into the compound 5 obtained in the step (3), performing coupling reaction, and after the reaction is finished, purifying to obtain a compound 7;
(5) adding triethylamine into the organic solvent of the compound 7 obtained in the step (4), carrying out deprotection reaction, and after the reaction is finished, purifying to obtain a compound shown in the formula I;
wherein the structure of compound 2 is:
the structure of compound 3 is:
compound 4 has the structure:
the structure of compound 5 is:
the structure of compound 7 is:
further, in the step (1), the nitrate is potassium nitrate; and/or the molar ratio of nitrate to 5-bromo-7-azaindole is 1.1: 1-2: 1, the mass-to-volume ratio of nitrate to concentrated sulfuric acid is 1: 10-1: 18 g/mL; and/or controlling the temperature to be-10-0 ℃ before adding the 5-bromo-7-azaindole, controlling the temperature to be 0 ℃ after adding the 5-bromo-7-azaindole, and stirring for 10-30 minutes.
Further, in the step (1), the molar ratio of the nitrate to the 5-bromo-7-azaindole is 1.4: 1, the mass-to-volume ratio of nitrate to concentrated sulfuric acid is 1: 14.3 g/mL; and/or controlling the temperature to be-5-0 ℃ before adding the 5-bromo-7-azaindole, controlling the temperature to be 0 ℃ after adding the 5-bromo-7-azaindole, and stirring for 15 minutes.
Further, in the step (2), the reducing agent is a metal reducing agent, and the organic solvent is absolute ethyl alcohol; and/or, the mole of compound 2 and reducing agent is 1: 3-1: 6, the molar ratio of the compound 2 to the ammonium chloride is 1: 8-1: 15, the mass-to-volume ratio of the compound 2 to the organic solvent is 1: 20-1: 60 g/mL; and/or heating to 50-80 ℃ under the protection of nitrogen under the reaction condition, and stirring for reacting for 2-6 hours.
Further, in the step (2), the reducing agent is zinc powder; and/or, the mole of compound 2 and reducing agent is 1: 5.1, the molar ratio of compound 2 to ammonium chloride is 1: 12.1, the mass-to-volume ratio of the compound 2 to the organic solvent is 1: 41.7 g/mL; and/or heating to 65 ℃ under the protection of nitrogen, and stirring for reacting for 4 hours.
Further, in the step (3), the organic solvent a is a mixed solvent of dichloromethane and N, N-dimethylformamide, the organic solvent b is tetrahydrofuran, and the organic solvent c is tetrahydrofuran; and/or the mass-volume ratio of the compound 4 to the organic solvent a is 1: 20-1: 40, the mass-to-volume ratio of the compound 4 to oxalyl chloride is 1.5: 1-3.5: 1g/mL, and the mass-to-volume ratio of the compound 3 to triethylamine is 0.5: 1-2: 1g/mL, and the mass-to-volume ratio of the compound 3 to the organic solvent b is 1: 10-1: 40g/mL, the mass-to-volume ratio of the compound 4 to the organic solvent c is 1: 10-1: 40 g/mL; and/or, the reaction conditions were room temperature overnight.
Further, in the step (3), in the organic solvent a, the mass-to-volume ratio of the compound 4 to the dichloromethane is 1: 30, the mixture ratio of the compound 4 to the N, N-dimethylformamide is 2.5 g/drop; and/or the mass-to-volume ratio of the compound 4 to oxalyl chloride is 2.5:1g/mL, and the mass-to-volume ratio of the compound 3 to triethylamine is 1: 1g/mL, and the mass-to-volume ratio of the compound 3 to the organic solvent b is 1: 30g/mL, and the mass-to-volume ratio of the compound 4 to the organic solvent c is 1: 15 g/mL.
Further, in the step (3), the purification process is as follows: the system after the end of the reaction was concentrated, the solvent was removed and the residue was then separated by means of a chromatographic column, eluting with dichloromethane: methanol 20: 1.
Further, in the step (4), the mass ratio of the compound 5 to the 3, 5-difluoroaniline is 3: 1-7: the mass ratio of the compound 5 to the 1,1 '-binaphthyl-2, 2' -bis-diphenylphosphine is 10: 1-15: 1, the mass ratio of the compound 5 to the cesium carbonate is 1.2: 1-2: 1, the mass ratio of the compound 5 to the palladium acetate is 40: 1-80: 1, the mass-to-volume ratio of the compound 5 to dioxane is 1: 4-1: 8 g/mL; and/or under the protection of nitrogen, heating to 80-120 ℃, and stirring for reaction for 20-30 hours.
Further, in the step (4), the mass ratio of the compound 5 to the 3, 5-difluoroaniline is 5.9: the mass ratio of the compound 5 to the 1,1 '-binaphthyl-2, 2' -bis-diphenylphosphine is 12.3: 1, the mass ratio of the compound 5 to the cesium carbonate is 1.6: 1, the mass ratio of the compound 5 to the palladium acetate is 69: 1, the mass-to-volume ratio of the compound 5 to dioxane is 1: 6.8 g/mL; and/or, the reaction condition is nitrogen protection, the temperature is heated to 100 ℃, and the reaction is stirred for 24 hours.
Further, in the step (4), the purification process is as follows: concentrating the system after the reaction is finished, removing the solvent, and purifying the residue by a chromatographic column, wherein the eluent ratio is 20: 1.
further, in the step (5), the organic solvent is methanol; and/or the mass volume ratio of the compound 7 to the organic solvent is 1: 10-1: 30g/mL, and the mass-to-volume ratio of the compound 7 to triethylamine is 1: 2-1: 6 g/mL; and/or the reaction temperature is 50-80 ℃.
Further, in the step (5), the mass-to-volume ratio of the compound 7 to the organic solvent is 1: 20g/mL, and the mass-to-volume ratio of the compound 7 to triethylamine is 1: 4 g/mL; and/or the reaction temperature is 65 ℃.
Further, in the step (5), the purification process is as follows: the system after the end of the reaction was concentrated, the solvent was removed and the residue was then separated by means of a chromatographic column, eluting with dichloromethane: methanol 10: 1.
Further, the method further comprises: adding acid into free alkali of the compound shown in the formula I, reacting, and forming salt to obtain pharmaceutically acceptable salt of the compound shown in the formula I.
Further, the acid is selected from hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, picric acid, citric acid, maleic acid, methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid.
The invention also provides a pharmaceutical composition for treating tumor, pain and inflammation, which is characterized in that: the compound is prepared by taking the compound as claimed in claim 1 as an active ingredient and adding pharmaceutically acceptable auxiliary materials.
The invention also provides a compound shown in the formula I or a pharmaceutically acceptable salt thereof, or a solvate thereof or a prodrug thereof, and application of the pharmaceutical composition as a protein kinase inhibitor.
Further, the use is for preventing or treating diseases related to the disregulation of the activity of the protein kinase.
Further, the disease is tumor, pain, inflammation.
Test results show that the compound shown in the structure of the formula I can obviously inhibit the enzyme activity of TRK at the molecular level, has obvious inhibition effect on the phosphorylation/activation of TRK at the cell level, and can obviously inhibit the growth of the nude mouse transplantation tumor of a human tumor cell strain.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention is described in further detail below with reference to examples, but it should not be construed that the scope of the above subject matter is limited to the examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1 is a graph of the growth inhibition of Tianrgitinib and the control compound LOXO-101 prepared in example 1 of the present invention on KM-12 nude mouse transplantable tumors;
FIG. 2 is a graph showing the effect of Tianrgitinib prepared in example 1 of the present invention and LOXO-101, a control compound, on the body weight of KM-12 tumor-bearing nude mice.
Detailed Description
The starting materials are all commercially available.
EXAMPLE 1 preparation of Compounds of formula I
Step (1): synthesis of Compound 2
Potassium nitrate (14 g, 0.140mol) and 200 ml of concentrated sulfuric acid are added into a 500 ml reaction bottle, the mixture is stirred and dissolved at room temperature, then the mixture is cooled to-5 ℃ to 0 ℃ in an ice water bath, 5-bromo-7-azaindole (20 g, 0.101mol) is slowly added, the mixture is stirred at 0 ℃ for 15 minutes after the dripping is finished, TLC shows that the reaction is complete, the reaction solution is dripped into ice water, a white-like solid is separated out, and the white-like solid is filtered and dried to obtain 3-nitro-5-bromo-7-azaindole (compound 2) with the weight of 24.44 g and the yield of 91.0%.
1H NMR(400MHz,CD3SOCD3)δ8.92(s,1H),8.61-8.57(m,2H).ESIMS m/z＝242.0, 244.0(M+1).
Step 2: synthesis of Compound 3
A500 ml reaction flask is added with compound 2(6.0 g, 0.025mol), zinc powder (8.3 g, 0.127mol), ammonium chloride (16 g, 0.302mol), 250 ml of absolute ethyl alcohol, protected by nitrogen, heated to 65 ℃, and stirred for reaction for 4 hours. Cooled to room temperature, filtered, and concentrated under reduced pressure to remove the solvent, to give 3-amino-5-bromo-7-azaindole (compound 3) in a weight of 5.0 g, 94% yield.
1H NMR(400MHz,CD3SOCD3)δ10.91(s,1H),8.21(d,J＝2.1,1H),8.18(d,J＝2.1, 1H),6.76(d,J＝2.1,1H),4.39(br,s,2H).ESIMS m/z＝212.0,214.0(M+1).
And step 3: synthesis of Compound 5
Compound 4(10 g, 0.024mol), 300 ml dichloromethane, 4 drops DMF were added to a 500 ml reaction flask, 4 ml oxalyl chloride was slowly dropped, after dropping, stirred at room temperature for 2 hours, and concentrated under reduced pressure to obtain acid chloride for use. Another 500 ml reaction flask was charged with Compound 3(5 g, 0.024mol), 5 ml triethylamine, and 150 ml tetrahydrofuran solution of the acid chloride was added dropwise with stirring. Stir overnight at room temperature after dropping.
The next morning was concentrated and the residue was purified by column chromatography (dichloromethane: methanol 20:1) to give the compound 5 as a white solid in a yield of 25% by weight 3.6 g.
1H NMR(400MHz,CD3SOCD3)δ10.91(s,1H),9.06(d,J＝2.0,1H),8.20(d,J＝2.1, 1H),7.94(d,J＝7.8Hz,1H),6.93-6.71(m,3H),3.80(ddd,J＝11.7,2.8,3.8,2H), 3.62-3.72(m,1H),3.49-3.23(m,6H),2.50-2.24(m,7H),1.90-1.86(m,2H), 1.41-1.20(m,2H).ESIMS m/z＝609.0,611.0(M+1).
And 4, step 4: synthesis of Compound 7
A250 ml reaction flask was charged with 3, 5-difluoroaniline (3.52 g, 27.3mmol), compound 5(20.7 g, 34.1mmol), 1,1 '-binaphthyl-2, 2' -bis-diphenylphosphine (1.69g, 2.73mmol), cesium carbonate (13.3 g, 4.1mmol), palladium acetate (0.3 g), dioxane 140 ml, under nitrogen, heated to 100 deg.C, and stirred for 24 hours. The solvent was removed by concentration under reduced pressure, and the residue was purified by column chromatography (dichloromethane: methanol 20:1) to give compound 7 as a white solid in a yield of 73.2% by weight of 17.9 g.
1H NMR(400MHz,CD3SOCD3)δ10.95(s,1H),9.57(s,1H),9.06(d,J＝2.0,1H), 8.23(d,J＝2.1,1H),7.95(d,J＝7.8Hz,1H),7.57(s,2H),6.92-6.72(m,3H),6.12(s, 1H),3.85(ddd,J＝11.7,2.8,3.8,2H),3.61-3.73(m,1H),3.46-3.23(m,6H), 2.52-2.24(m,7H),1.94-1.86(m,2H),1.41-1.23(m,2H).ESIMS m/z＝658.2(M+1).
And 5: synthesis of Compounds of formula I
A250 ml reaction flask was charged with 5g of compound 7,100 ml of methanol, 20 ml of triethylamine, heated to 65 ℃ and TLC monitored until compound 7 disappeared and the reaction was complete.
The methanol was removed by concentration under reduced pressure, and the residue was purified by column chromatography (dichloromethane: methanol 10:1) to give a white solid as the compound represented by formula I.
1H NMR(400MHz,CD3SOCD3)δ10.95(s,1H),9.57(s,1H),9.06(d,J＝2.0,1H), 8.23(d,J＝2.1,1H),7.93(d,J＝7.8Hz,1H),7.53(s,2H),6.92-6.71(m,3H),6.52 (s,1H),6.13(s,1H),3.85(ddd,J＝11.7,2.8,3.8,2H),3.61-3.73(m,1H), 3.42-3.26(m,6H),2.51-2.22(m,7H),1.94-1.87(m,2H),1.43-1.21(m,2H).ESIMS m/z＝562.3(M+1).
Test example 1: effect of the Compound of formula 1 on the TRK enzymatic Activity at molecular level
(1) Materials: the compound of formula I prepared in example 1 of the present invention, bizarinib; control compound LOXO-101.
(2) The method comprises the following steps: the inhibition ratio of the sample was obtained by the following formula:
IC50 values were calculated by a four parameter fit through the inhibition curve.
(3) Results of the experiment
The enzyme activity test at a molecular level shows that the Tianqitinib has a good inhibition effect on TRK tyrosine kinase when the concentration is at a nanomolar level, is stronger than a positive control compound LOXO-101, and is a TRK tyrosine kinase inhibitor with stronger action.
TABLE 1 half inhibitory concentration of the compound of formula I, gefitinib, prepared in accordance with the present invention on TRK-kinase
Test example 2: effect of the Compound represented by formula 1 on growth inhibition of human Colon cancer cell KM-12 nude mouse transplanted tumor
(1) Materials: the compound of formula I prepared in example 1 of the present invention, bizarinib; control compound LOXO-101.
(2) The method comprises the following steps: tumor length (a), width (B) were measured twice weekly, and tumor volume V ═ a × B was calculated therefrom2/2. The calculation of Relative Tumor Volume (RTV) follows: RTV ═ Vt/V0,VtTumor volume at a given time, V0The resulting tumor volumes were measured before cage dosing. The relative tumor proliferation rate T/C (%) was used as an index for evaluating antitumor activity, and T/C (%) was the average RTV of the administration group/the average RTV of the control group × 100%. If the T/C% is less than or equal to 60%, the statistical detection shows significant difference, and the in vivo anti-tumor effect is considered to be obvious. Meanwhile, the weight of each group of nude mice is weighed twice a week to preliminarily evaluate the toxic and side effects of the drug.
(3) Results of the experiment
The compound, varitinib and positive control LOXO-101, showed very significant growth inhibition in this transplantation tumor model at each dose, with varitinib having a relatively weaker tumor inhibition effect than the positive control LOXO-101 (fig. 1). One mouse in the group of 100mg/kg of nitstrinib died on day 9 of administration, and the weight of the mouse did not significantly decrease and the appearance of the mouse was not significantly abnormal. The weight average of mice in each group of Tianrgitinib and LOXO-101 did not decrease significantly (FIG. 2).
In conclusion, the compound with the structure shown in the formula I, which is prepared by the invention, can obviously inhibit the enzyme activity of TRK at a molecular level, has an obvious inhibition effect on the phosphorylation/activation of TRK at a cell level, and can obviously inhibit the growth of a human tumor cell strain nude mouse transplantation tumor.
Claims (16)
1. An amide substituted azaindole compound or a pharmaceutically acceptable salt thereof, the compound having the structure of formula I:
2. a process for the preparation of a compound according to claim 1, characterized in that: the method comprises the following steps:
(1) adding 5-bromo-7-azaindole into a solution of nitrate and concentrated sulfuric acid to perform nitration reaction, and after the reaction is finished, dropping the system into ice water to separate out a solid to obtain a compound 2;
(2) adding a reducing agent and ammonium chloride into the compound 2 obtained in the step (1), adding an organic solvent, carrying out reduction reaction, filtering after the reaction is finished, taking liquid, concentrating and removing the solvent to obtain a compound 3;
(3) i, dissolving the compound 4 in an organic solvent a, dropwise adding oxalyl chloride, stirring, and concentrating the liquid for later use; adding triethylamine and an organic solvent b into the compound 3 obtained in the step (2); iii, under stirring, dissolving the standby system obtained in the step i in an organic solvent c, and then dripping the organic solvent c into the system obtained in the step ii to perform condensation reaction; after the reaction is finished, purifying to obtain a compound 5;
(4) adding 3, 5-difluoroaniline, 1 '-binaphthyl-2, 2' -bis-diphenylphosphine, cesium carbonate, palladium acetate and dioxane into the compound 5 obtained in the step (3), performing coupling reaction, and after the reaction is finished, purifying to obtain a compound 7;
(5) adding triethylamine into the organic solvent of the compound 7 obtained in the step (4), carrying out deprotection reaction, and after the reaction is finished, purifying to obtain a compound shown in the formula I;
wherein the structure of compound 2 is:
the structure of compound 3 is:
compound 4 has the structure:
the structure of compound 5 is:
the structure of compound 7 is:
3. the method of claim 2, wherein: in the step (1), the nitrate is potassium nitrate; and/or the molar ratio of nitrate to 5-bromo-7-azaindole is 1.1: 1-2: 1, the mass-to-volume ratio of nitrate to concentrated sulfuric acid is 1: 10-1: 18 g/mL; and/or controlling the temperature to be-10-0 ℃ before adding the 5-bromo-7-azaindole, controlling the temperature to be 0 ℃ after adding the 5-bromo-7-azaindole, and stirring for 10-30 minutes; or, in the step (2), the reducing agent is a metal reducing agent, and the organic solvent is absolute ethyl alcohol; and/or, the mole of compound 2 and reducing agent is 1: 3-1: 6, the molar ratio of the compound 2 to the ammonium chloride is 1: 8-1: 15, the mass-to-volume ratio of the compound 2 to the organic solvent is 1: 20-1: 60 g/mL; and/or heating to 50-80 ℃ under the protection of nitrogen under the reaction condition, and stirring for reacting for 2-6 hours.
4. The production method according to claim 3, characterized in that: in the step (1), the molar ratio of the nitrate to the 5-bromo-7-azaindole is 1.4: 1, the mass-to-volume ratio of nitrate to concentrated sulfuric acid is 1: 14.3 g/mL; and/or controlling the temperature to be-5-0 ℃ before adding the 5-bromo-7-azaindole, controlling the temperature to be 0 ℃ after adding the 5-bromo-7-azaindole, and stirring for 15 minutes; or, in the step (2), the reducing agent is zinc powder; and/or, the mole of compound 2 and reducing agent is 1: 5.1, the molar ratio of compound 2 to ammonium chloride is 1: 12.1, the mass-to-volume ratio of the compound 2 to the organic solvent is 1: 41.7 g/mL; and/or heating to 65 ℃ under the protection of nitrogen, and stirring for reacting for 4 hours.
5. The method of claim 2, wherein: in the step (3), the organic solvent a is a mixed solvent of dichloromethane and N, N-dimethylformamide, the organic solvent b is tetrahydrofuran, and the organic solvent c is tetrahydrofuran; and/or the mass-volume ratio of the compound 4 to the organic solvent a is 1: 20-1: 40, the mass-to-volume ratio of the compound 4 to oxalyl chloride is 1.5: 1-3.5: 1g/mL, and the mass-to-volume ratio of the compound 3 to triethylamine is 0.5: 1-2: 1g/mL, and the mass-to-volume ratio of the compound 3 to the organic solvent b is 1: 10-1: 40g/mL, and the mass-to-volume ratio of the compound 4 to the organic solvent c is 1: 10-1: 40 g/mL; and/or, the reaction condition is stirring overnight at room temperature; or, in the step (3), in the organic solvent a, the mass-to-volume ratio of the compound 4 to the dichloromethane is 1: 30, the mixture ratio of the compound 4 to the N, N-dimethylformamide is 2.5 g/drop; or, in the step (3), the purification process is as follows: the system after the end of the reaction was concentrated, the solvent was removed and the residue was then separated by means of a chromatographic column, eluting with dichloromethane: methanol 20: 1.
6. The method of claim 5, wherein: in the step (3), the mass-to-volume ratio of the compound 4 to oxalyl chloride is 2.5:1g/mL, and the mass-to-volume ratio of the compound 3 to triethylamine is 1: 1g/mL, and the mass-to-volume ratio of the compound 3 to the organic solvent b is 1: 30g/mL, and the mass-to-volume ratio of the compound 4 to the organic solvent c is 1: 15 g/mL.
7. The method of claim 2, wherein: in the step (4), the mass ratio of the compound 5 to the 3, 5-difluoroaniline is 3: 1-7: the mass ratio of the compound 5 to the 1,1 '-binaphthyl-2, 2' -bis-diphenylphosphine is 10: 1-15: 1, the mass ratio of the compound 5 to the cesium carbonate is 1.2: 1-2: 1, the mass ratio of the compound 5 to the palladium acetate is 40: 1-80: 1, the mass-to-volume ratio of the compound 5 to the dioxane is 1: 4-1: 8 g/mL; and/or under the protection of nitrogen, heating to 80-120 ℃, and stirring for reaction for 20-30 hours; or, in the step (4), the purification process is as follows: concentrating the system after the reaction is finished, removing the solvent, and purifying the residue by a chromatographic column, wherein the eluent ratio is 20: 1.
8. the method of claim 7, wherein: in the step (4), the mass ratio of the compound 5 to the 3, 5-difluoroaniline is 5.9: the mass ratio of the compound 5 to the 1,1 '-binaphthyl-2, 2' -bis-diphenylphosphine is 12.3: 1, the mass ratio of the compound 5 to the cesium carbonate is 1.6: 1, the mass ratio of the compound 5 to the palladium acetate is 69: 1, the mass-to-volume ratio of the compound 5 to the dioxane is 1: 6.8 g/mL; and/or, the reaction condition is nitrogen protection, the temperature is heated to 100 ℃, and the reaction is stirred for 24 hours.
9. The method of claim 2, wherein: in the step (5), the organic solvent is methanol; and/or the mass volume ratio of the compound 7 to the organic solvent is 1: 10-1: 30g/mL, and the mass-to-volume ratio of the compound 7 to triethylamine is 1: 2-1: 6 g/mL; and/or the reaction temperature is 50-80 ℃; or, in the step (5), the purification process is as follows: the system after the end of the reaction was concentrated, the solvent was removed and the residue was then separated by means of a chromatographic column, eluting with dichloromethane: methanol 10: 1.
10. The method of claim 9, wherein: in the step (5), the mass-to-volume ratio of the compound 7 to the organic solvent is 1: 20g/mL, and the mass-to-volume ratio of the compound 7 to triethylamine is 1: 4 g/mL; and/or the reaction temperature is 65 ℃.
11. The production method according to any one of claims 2 to 10, characterized in that: the method further comprises the following steps: adding acid into free alkali of the compound shown in the formula I, reacting, and forming salt to obtain pharmaceutically acceptable salt of the compound shown in the formula I.
12. The method of claim 11, wherein: the acid is selected from hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, picric acid, citric acid, maleic acid, methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid.
13. A pharmaceutical composition for treating tumor, pain and inflammation, which is characterized in that: the compound is prepared by taking the compound as claimed in claim 1 as an active ingredient and adding pharmaceutically acceptable auxiliary materials.
14. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof, the pharmaceutical composition of claim 13 for the preparation of a protein kinase inhibitor.
15. Use according to claim 14, characterized in that: the application is the application in preparing the medicine for preventing or treating the diseases related to the activity disorder of the protein kinase.
16. The use according to claim 15, characterized in that: the disease is tumor, pain and inflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910028222.7A CN109942574B (en) | 2019-01-11 | 2019-01-11 | Tianqitinib and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910028222.7A CN109942574B (en) | 2019-01-11 | 2019-01-11 | Tianqitinib and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109942574A CN109942574A (en) | 2019-06-28 |
| CN109942574B true CN109942574B (en) | 2022-04-01 |
Family
ID=67007274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910028222.7A Active CN109942574B (en) | 2019-01-11 | 2019-01-11 | Tianqitinib and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109942574B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| WO2009081197A1 (en) * | 2007-12-21 | 2009-07-02 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
| CN103509017A (en) * | 2008-10-22 | 2014-01-15 | 阵列生物制药公司 | Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors |
| WO2014016434A1 (en) * | 2012-07-27 | 2014-01-30 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
-
2019
- 2019-01-11 CN CN201910028222.7A patent/CN109942574B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| WO2009081197A1 (en) * | 2007-12-21 | 2009-07-02 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
| CN103509017A (en) * | 2008-10-22 | 2014-01-15 | 阵列生物制药公司 | Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors |
| WO2014016434A1 (en) * | 2012-07-27 | 2014-01-30 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109942574A (en) | 2019-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11548896B2 (en) | Heterocyclic compounds as RET kinase inhibitors | |
| CN111484480B (en) | Polycyclic derivative inhibitor, preparation method and application thereof | |
| EP3609898B1 (en) | Compounds useful as ret inhibitors | |
| CA2473026C (en) | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | |
| KR101481388B1 (en) | Novel aminopyrimidine derivatives as PLK1 inhibitors | |
| EP3255046B1 (en) | Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor | |
| JP2006519814A (en) | Substituted 8′-pyridinyl-dihydrospiro- [cycloalkyl] -pyrimido [1,2-a] pyrimidin-6-one and 8′-pyrimidinyl-dihydrospiro- [cycloalkyl] -pyrimido [1,2-a ] Pyrimidin-6-one derivatives | |
| JP7009504B2 (en) | Novel aminoimidazolipyridine derivatives as Janus kinase inhibitors and their pharmaceutical use | |
| CN113527299B (en) | Nitrogen-containing condensed ring compound, preparation method and application | |
| AU2020342189A1 (en) | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | |
| CN110105356B (en) | Azaindole compound and preparation method and application thereof | |
| CN109942574B (en) | Tianqitinib and preparation method and application thereof | |
| CN111499613B (en) | N-carboxamide derivatives, method for the production thereof and their use in medicine | |
| CN111718325A (en) | 2,4, 5-substituted pyrimidine compound and preparation method and application thereof | |
| KR102629854B1 (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| CN108066340B (en) | Pharmaceutical composition | |
| CN112939966B (en) | Pyrimidine derivatives, their preparation and use | |
| CN112384506B (en) | Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology | |
| US20220354859A1 (en) | Substituted imidazoquinoxaline compounds and uses thereof | |
| CN116730943A (en) | Compound and medical application thereof | |
| CN116655636A (en) | Five-membered and six-membered heterocyclic compounds and application thereof as protein kinase inhibitors | |
| NZ787350A (en) | Heterocyclic compounds as ret kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: No.2, building 10, Tianfu Pioneer Park, No.2, Tianyu Road, high tech Zone, Chengdu, Sichuan 610000 Patentee after: CHENGDU ACHI BIOPHARMACEUTICAL TECHNOLOGY Co.,Ltd. Patentee after: Chengdu Tiantaishan Pharmaceutical Co.,Ltd. Patentee after: SHANGHAI PUYUAN MEDICAL TECHNOLOGY CENTER Address before: No.2, building 10, Tianfu Pioneer Park, No.2, Tianyu Road, high tech Zone, Chengdu, Sichuan 610000 Patentee before: CHENGDU ACHI BIOPHARMACEUTICAL TECHNOLOGY Co.,Ltd. Patentee before: CHENGDU TIANTAISHAN PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI PUYUAN MEDICAL TECHNOLOGY CENTER |
|
| CP01 | Change in the name or title of a patent holder |